cabazitaxel and Leukemia--Myeloid--Acute

Improvement in survival has been achieved for children and adolescents with AML but is largely attributed to enhanced supportive care as opposed to the development of better treatment regimens. High risk subtypes continue to have poor outcomes with event free survival rates <40% despite the use of high intensity chemotherapy in combination with hematopoietic stem cell transplant. Here we combine high-throughput screening, intracellular accumulation assays, and in vivo efficacy studies to identify therapeutic strategies for pediatric AML. We report therapeutics not currently used to treat AML, gemcitabine and cabazitaxel, have broad anti-leukemic activity across subtypes and are more effective relative to the AML standard of care, cytarabine, both in vitro and in vivo. JAK inhibitors are selective for acute megakaryoblastic leukemia and significantly prolong survival in multiple preclinical models. Our approach provides advances in the development of treatment strategies for pediatric AML.

Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cell Line, Tumor; Child; Child, Preschool; Cytarabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; High-Throughput Screening Assays; Humans; Infant; Janus Kinase Inhibitors; Leukemia, Experimental; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Taxoids; Whole-Body Irradiation; Xenograft Model Antitumor Assays; Young Adult